Expression of ATRX and Ki-67 in glioma and their clinical significance

HU Zhi-min; LIU Jin-xia; LOU Jin-feng

doi:10.13798/j.issn.1009-153X.2024.09.008

Abstract：Objective To investigate the expression of ATRX and Ki-67 in human gliomas and their clinical significance. Methods Fifty-one specimens of gliomas that were surgically resected and diagnosed by postoperative pathological examination from January 2018 to January 2023 were collected. The expression of ATRX and Ki-67 was detected by immunohistochemical staining. The postoperative follow-up period ranged from 0.5 to 50 months,with a median of 16 months (IQR:5～28 months),and the survival status of the patients was recorded. Results Of the 51 glioma patients,3 were WHO grade Ⅰ,13 were grade Ⅱ,16 were grade Ⅲ,and 19 were grade Ⅳ. The positive rate of Ki-67 in WHO grade Ⅲ and Ⅳ gliomas (80.0％,28/35) was significantly higher than that in WHO grade Ⅰ and Ⅱ gliomas (50.0％,8/16;P=0.029);the positive rate of ATRX in WHO grade Ⅲ and Ⅳ gliomas (68.6％,24/35) was lower than that in WHO grade Ⅰ and Ⅱ gliomas (87.5％,14/16),but without statistical significance (P=0.185). Multivariate Cox regression analysis revealed that negative expression of Ki-67 (RR=0.408;95％ CI 0.214～0.778;P=0.006) was an independent protective factor for poor prognosis of glioma,and negative expression of ATRX (RR=2.189;95％ CI 0.082～4.431;P=0.029) was an independent risk factor for poor prognosis of glioma. Kaplan-Meier survival curve analysis demonstrated that the median survival times of gliomas with negative expression of Ki-67 and positive expression of ATRX were significantly prolonged (P<0.05). Conclusion The expressions of ATRX and Ki-67 are correlated with the pathological grade and prognosis of glioma patients and can serve as reference indicators for pathological classification and prognosis evaluation of glioma patients.